Search

Your search keyword '"Nasrallah, Gheyath K."' showing total 102 results

Search Constraints

Start Over You searched for: Author "Nasrallah, Gheyath K." Remove constraint Author: "Nasrallah, Gheyath K." Topic covid-19 Remove constraint Topic: covid-19
102 results on '"Nasrallah, Gheyath K."'

Search Results

1. Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.

2. BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.

3. Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design.

4. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant.

5. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.

6. Antibody-dependent enhancement (ADE) of SARS-CoV-2 in patients exposed to MERS-CoV and SARS-CoV-2 antigens.

7. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.

8. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.

9. SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study.

10. Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study.

11. History of primary-series and booster vaccination and protection against Omicron reinfection.

12. Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections.

13. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.

14. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.

15. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.

16. Influenza prevalence and vaccine efficacy among diabetic patients in Qatar.

17. BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents.

18. Protection against Reinfection with the Omicron BA.2.75 Subvariant.

19. Duration of immune protection of SARS-CoV-2 natural infection against reinfection.

20. Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection.

21. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.

22. Covid-19 Vaccine Protection among Children and Adolescents in Qatar.

23. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.

24. Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2.

25. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.

26. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections.

27. Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections.

28. Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.

29. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage.

30. COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar.

31. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.

32. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

33. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.

34. Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.

35. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.

36. Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience.

37. Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?

38. Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.

39. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.

40. Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays.

41. Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.

42. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study.

43. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.

44. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.

45. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.

46. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.

47. Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France.

48. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.

49. Effect of multiple freeze-thaw cycles on the detection of anti-SARS-CoV-2 IgG antibodies.

50. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.

Catalog

Books, media, physical & digital resources